Octreoscan in patients with bronchial carcinoid tumours

Granberg, Dan; Sundín, Anders; Janson, Eva Tiensuu; Öberg, Kjell; Skogseid, Britt; Westlin, Jan‐Erik

doi:10.1046/j.1365-2265.2003.01931.x

Cited by 112 publications

(54 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study evaluating the tissue distribution of sst 2A and sst 3 in a large series (O200 cases) of pulmonary NET with clinically aggressive features (Righi et al 2010) confirmed previous data from small series, showing a decrease in the expression of sst 2 and sst 3 from lowgrade/intermediate-grade to high-grade tumors, and confirming a good correlation between immunohistochemical results and octreotide scintigraphy (Reisinger et al 1998, Granberg et al 2003, Reubi & Waser 2003.…”

Section: Sstr Expression In Endocrine Tumorssupporting

confidence: 65%

The role of somatostatin and dopamine D2 receptors in endocrine tumors

Gatto¹,

Hofland²

2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

Somatostatin (SS) and dopamine (DA) receptors have been highlighted as two critical regulators in the negative control of hormonal secretion in a wide group of human endocrine tumors. Both families of receptors belong to the superfamily of G protein-coupled receptors and share a number of structural and functional characteristics. Because of the generally reported high expression of somatostatin receptors (SSTRs) in neuroendocrine tumors (NET), somatostatin analogs (SSA) have a pronounced role in the medical therapy for this class of tumors, especially pituitary adenomas and well-differentiated gastroenteropancreatic NET (GEP NET). Moreover, NET express not only SSTR but also frequently dopamine receptors (DRs), and DA agonists targeting the D 2 receptor (D 2 ) have been demonstrated to be effective in controlling hormone secretion and cell proliferation in in vivo and in vitro studies. The treatment with SSAs combined with DA agonists has already been demonstrated efficacious in a subgroup of patients with GH-secreting pituitary adenomas and few reported cases of carcinoids. The recent availability of new selective and universal SSA and DA agonists, as well as the chimeric SS/DA compounds, may shed new light on the potential role of SSTR and D 2 as combined targets for biotherapy in NET. This review provides an overview of the latest studies evaluating the expression of SSTR and DR in NET, focusing on their co-expression and the possible clinical implications of such co-expression. Moreover, the most recent insights in SSTR and D 2 pathophysiology and the future perspectives for treatment with SSA, DA agonists, and SS/DA chimeric compounds are discussed.

show abstract

Section: Sstr Expression In Endocrine Tumorssupporting

confidence: 65%

The role of somatostatin and dopamine D2 receptors in endocrine tumors

Gatto¹,

Hofland²

2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…26 There is also evidence to suggest that octreotide scans are useful in occult ACTH-secreting tumors, including those of bronchial origin. [26][27][28] …”

Section: Presentationmentioning

confidence: 99%

Pulmonary neuroendocrine/carcinoid tumors

Bertino

Confer

Colonna

et al. 2009

Cancer

133

123

View full text Add to dashboard Cite

Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well-differentiated bronchial neuroendocrine tumors (also called carcinoid tumors) are reported to account for approximately 25% of all neuroendocrine tumors, they represent only 1% to 2% of all lung cancers. The epidemiology, clinical behavior, and treatment of neuroendocrine carcinoid tumors differ significantly from other lung malignancies. In this article, the recent data regarding these tumors were reviewed with attention to the treatment modalities used. Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) Well-differentiated neuroendocrine, or carcinoid, tumors are a unique class of malignancies capable of producing hormones identical to those from the nervous system. Although the first carcinoid tumor described was in the ileum, neuroendocrine malignancies are a family of malignancies found throughout the body. Tumors of the bronchial tree in particular account for approximately 25% of all well-differentiated neuroendocrine tumors (Table 1). [1][2][3] However, compared with other malignancies of the bronchoalveolar tree, these well-differentiated neuroendocrine tumors are rare, accounting for only 1% of all lung cancers. 3 The pathologic spectrum of neuroendocrine malignancies ranges from low-grade carcinoid to aggressive small cell lung cancer. The low-grade and intermediate-grade neuroendocrine malignancies, also known as typical and atypical carcinoid, will be the focus of this review. The distinct features of this malignancy include its pathologic characteristics, clinical behavior, epidemiology, prognosis, and treatment.

show abstract

“…They may also be imaged with octreoscan. 11 However, specificity is limited because scintigraphy is positive in many other tumours, and not all carcinoid tumours that express somatostatin receptors by immunohistochemistry test positive with octreoscan.…”

Section: Discussionmentioning

confidence: 99%